

08/105444

Abstract

Vaccines capable of eliciting an immune  
antitumor response for prostate tumors are disclosed. The  
active ingredient in such vaccines is selected from the  
5 group consisting of

at least one antigen overrepresented in the  
prostate gland or an immunologically effective portion  
thereof;

an expression system capable of generating in  
10 *situ* said antigen or portion; and

an antiidiotypic antibody or fragment thereof  
which mimics said antigen or portion.